Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Herzog

Cardiovascular Disease Minneapolis, MN Medical Doctor

NPI 1417996588 CMS profile 200725

715 S 8Th St, Minneapolis, MN 55404

Open in the dashboard

General payments

$157,144

128 records reported · program years 2019–2025

Research payments

$30,258

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$39,474 paid to institutions, not to them · program year 2020

Through program year 2025, Charles Herzog of Minneapolis, MN is reported in the CMS Open Payments database as having received $157,144 across 128 general payments and $30,258 in research payments paid to them. Separately, studies naming them as principal investigator received $39,474 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,245 2
2024 General $9,670 4
2023 General $14,871 6
2022 General $26,712 19
2021 General $21,509 18
2020 General $45,707 20
2019 General $29,430 59
2019 Research $30,258 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Herzog
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Charles Herzog were reported at $9,245. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Charles Herzog Cardiovascular Disease median Middle half National median
2019 $29,430 $450 $127–$1,392 $163
2020 $45,707 $242 $77–$751 $114
2021 $21,509 $335 $101–$1,037 $132
2022 $26,712 $395 $121–$1,211 $149
2023 $14,871 $443 $136–$1,283 $160
2024 $9,670 $450 $136–$1,323 $164
2025 $9,245 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $52,113 44 payments
  2. Merck Sharp & Dohme Corporation $35,904 18 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $35,202 32 payments
  4. Novo Nordisk Inc $7,065 1 payment
  5. NxStage Medical, Inc. $7,065 21 payments
  6. Pfizer Inc. $6,350 2 payments
  7. Amgen Inc. $5,500 2 payments
  8. Relypsa, Inc. $3,864 2 payments
  9. E.R. Squibb & Sons, L.L.C. $3,600 1 payment
  10. AstraZeneca UK Limited $481 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $140,496 39 payments
  2. Travel and Lodging $8,037 38 payments
  3. Honoraria $6,000 1 payment
  4. Food and Beverage $2,612 50 payments
Products named General payments · program years 2019–2025
  1. LOKELMA $43,080 36 payments
  2. Kerendia $28,646 30 payments
  3. Non-Covered $6,556 2 payments
  4. ELIQUIS $6,350 2 payments
  5. Repatha $5,500 2 payments
  6. System One $4,065 19 payments
  7. Veltassa $3,864 2 payments
  8. NXSTAGE SYSTEM ONE $3,000 2 payments
  9. FARXIGA $2,148 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Relypsa, Inc. $29,605 1 payment
  2. Amgen Inc. $652 1 payment

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$13,757

Medicare's payments for the services billed

Medicare patients

238

Average age 68

Services billed

306

106 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 47%
Arthritis 45%
Ischemic heart disease 43%
Chronic kidney disease 41%
Depression 39%
Diabetes 36%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record